| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
BridgeBio Pharma, Inc.$85.89
-4.28 (-4.75%)
C 53Pipeline Score Richly Valued Biotech · Commercial
Market Cap
12.51 B
EPS
-3.75
P/E Ratio
-17.05 $
Value Trade
178.58 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
194.51 M
R&D Expenses
126.64 M
Operating CF
-197.28 M
Total Assets
1.37 B
Total Liabilities
3.64 B
Equity
-2.28 B
D/E Ratio
12,345
0.32 %
Week
-9.8 %
1 Month
-2.14 %
3 Month
6.93 %
6 Month
17.55 %
5 Year
125.81 %
All Time
Cash Data
Cash Position
940.19 M
Monthly Burn
65.76 M
Runway
12.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
6.38 M
52 Week Range
37.57 - 84.94
% held by Insiders
13.69 %
% held by Institutions
91.22 %
Enterprise Value
14.97 B
Total Shares
195.72 M
Short %
16.16 %
Float Shares
149.14 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BridgeBio Pharma, Inc.
650Total events
13Upcoming
205Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 13
2027
T2Trial Initiation
New TTR amyloid depleter antibody program expected to advance into clinic between 2027-2028
TBD
T2Timing Guidance
More data on Attruby benefit for ATTR-CM patients planned for future medical meetings
TBD
T2Oral Presentation
Company plans to present detailed FORTIFY results at a future medical meeting
Event history 637
Q3 2026
●Trial InitiationEncaleretTrial
Phase 3 RECLAIM-HP study to be initiated in 2H 2026
chronic hypoparathyroidismsource ↗
Q3 2026
◆NDA SubmissionInfigratinibApprovedRegulatory Filing
NDA submission planned for infigratinib in achondroplasia
achondroplasiasource ↗
Q3 2026
◆EU MAA SubmissionInfigratinibApprovedEx-US Regulatory
MAA submission planned for infigratinib in achondroplasia
achondroplasiasource ↗
Q3 2026
◆Full ResultsInfigratinibApprovedClinical Data
Phase 2 data expected in 2H 2026
hypochondroplasiasource ↗
Q3 2026
◆Topline ReadoutInfigratinibApprovedClinical Data
Phase 2 data from ACCEL 2 3 expected in second half of 2026
hypochondroplasiasource ↗
Jun 29, 2026
◆Oral PresentationInfigratinibApprovedPresentation
Oral presentation on health-related quality of life from PROPEL study at ICCBH 2026
achondroplasiasource ↗
Jun 29, 2026
◆Poster PresentationPresentation
Poster on ACCEL observational study in hypochondroplasia at ICCBH 2026
hypochondroplasiasource ↗
Jun 28, 2026
◆Late-BreakerInfigratinibApprovedPresentation
Late-breaking oral presentation of additional positive data from PROPEL 3 at ICCBH 2026
achondroplasiasource ↗
Jun 28, 2026
◆Poster PresentationInfigratinibApprovedPresentation
Poster on design of PROPEL Infant and Toddler study at ICCBH 2026
achondroplasiasource ↗
May 27, 2026
▲FDA Filing AcceptedBBP-418Regulatory Filing
FDA accepted NDA for BBP-418 with Priority Review
LGMD2I/R9source ↗
May 27, 2026
▲AdCom CancelledBBP-418Advisory Committee
FDA not planning to hold advisory committee meeting
LGMD2I/R9source ↗
May 27, 2026
Drug Pipeline Intelligence
C53
Pipeline Score $1.7B
Pipeline ValueRichly Valued
Valuation Signal10
Drugs Scored0.1x
rNPV / MCap Top 81%
Mid Cap (rank 174 of 911)
Percentile RankBridgeBio Pharma, Inc. carries a moderate pipeline score (53/100), with $2.0B risk-adjusted pipeline value, led by Infigratinib in Hypochondroplasia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infigratinib /kg Small molecule | Achondroplasia | Phase 3 | NCT04265651 | 90% | $580M | COMPLETED | 498 | - | - | Oct 21, 2024 | - | Oct 22, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
acoramidis | ATTR-CM | Phase 3 | 2026-05-11 | 34% reduction in cardiovascular hospitalizations compared to tafamidis; sTTR variability 9.5% vs. 12.8%; p<0.001; 41% reduction in outpatient worsening heart failure (HR 0.59, 95% CI 0.46–0.75; p < 0.0001) Read More | Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure Read More | |
acoramidis | ATTR-CM | Phase 3 | 2026-05-11 | 34% reduction in cardiovascular hospitalizations compared to tafamidis; sTTR variability 9.5% vs. 12.8%; p<0.001; 41% reduction in outpatient worsening heart failure (HR 0.59, 95% CI 0.46–0.75; p < 0.0001) Read More | Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure Read More | |
acoramidis | ATTR-CM | Phase 3 | 2026-05-11 | 34% reduction in cardiovascular hospitalizations compared to tafamidis; sTTR variability 9.5% vs. 12.8%; p<0.001; 41% reduction in outpatient worsening heart failure (HR 0.59, 95% CI 0.46–0.75; p < 0.0001) Read More | Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BBIOBridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
BridgeBio Pharma will present positive results from the Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia at the ICCBH 2026. The presentation will include a late-breaking oral session and several posters highlighting various aspects of achondroplasia and related conditions. The event will take place in Montreal from June 27-30, 2026.
Read more →BBIOBridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
BridgeBio Pharma announced that the FDA has accepted its New Drug Application for BBP-418, an oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a Priority Review designation. The PDUFA target action date is set for November 27, 2026. If approved, BBP-418 would be the first therapy for this condition, demonstrating strong efficacy in clinical trials.
Read more →BBIOBridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 - Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encal
BridgeBio has submitted a New Drug Application (NDA) to the FDA for encaleret, potentially the first treatment for individuals with autosomal dominant hypocalcemia type 1 (ADH1). The Phase 3 CALIBRATE trial demonstrated significant efficacy, with 76% of participants achieving target calcium levels compared to only 4% with conventional therapies. The company plans a U.S. launch in early 2027, supported by a growing diagnosed population. Additionally, BridgeBio aims to further develop encaleret for chronic hypoparathyroidism and pediatric ADH1.
Read more →BBIO▼ -5.6%on this newsshared move
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
BridgeBio Pharma announced positive results from the Phase 3 ATTRibute-CM study, showcasing acoramidis' ability to significantly reduce sTTR variability and improve clinical outcomes in patients with ATTR-CM. The treatment demonstrated a 34% reduction in cardiovascular hospitalizations compared to tafamidis and showed early effects on outpatient worsening heart failure. These findings reinforce acoramidis' potential as a disease-modifying therapy.
Read more →BBIOBridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
BridgeBio Pharma reported a strong financial performance for Q1 2026, with total revenues of $194.5 million, largely driven by the success of its product Attruby. The company is preparing for three major product launches and has initiated a stock repurchase program due to its undervalued stock. Despite the positive outlook, operating costs have risen significantly, contributing to a net loss for the quarter.
Read more →BBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma announced the approval of equity grants under Nasdaq Listing Rule 5635(c)(4) for 52 new employees. The compensation committee approved a total of 115,007 shares in restricted stock units. A quarter of these shares will vest by May 16, 2027, with additional quarterly vesting contingent on continued employment. This initiative reflects the company's strategy to attract and retain talent amidst its focus on developing medicines for genetic conditions.
Read more →BBIOBridgeBio to Participate in May and June Investor Conferences
BridgeBio Pharma, Inc. will participate in several healthcare investor conferences in May and June 2026. Key events include the BofA Securities Health Care Conference, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference. The management team will conduct fireside chats, and live webcasts will be available on their website.
Read more →BBIOBridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
BridgeBio Pharma announced it will present primary results from the Phase 3 CALIBRATE trial of encaleret at the 2026 European Congress of Endocrinology. The trial focuses on individuals with autosomal dominant hypocalcemia type 1 (ADH1). Additional presentations will cover genetic testing and quality of life measures related to hypoparathyroidism.
Read more →BBIOBridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
BridgeBio Pharma is set to present new data from the Phase 3 ATTRibute-CM study on acoramidis at the Heart Failure 2026 conference in Barcelona. The presentations will focus on the drug's effects on heart failure outcomes and biomarkers. Acoramidis is already approved in multiple regions, highlighting its significance in treating transthyretin amyloid cardiomyopathy.
Read more →BBIOBridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
BridgeBio Pharma, Inc. will announce its first quarter 2026 financial results and business updates on May 7, 2026, after market close. A conference call is scheduled for the same day at 4:30 pm ET. The event will be available via a live webcast and will be accessible for 30 days post-event.
Read more →BBIO▼ -6.5%on this newsshared move
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
BridgeBio Pharma has initiated a national campaign to raise awareness about ATTR-CM, a heart condition often misdiagnosed. The campaign features Morgan Freeman and Howard H. White, emphasizing the importance of recognizing symptoms for earlier diagnosis. The initiative aims to improve outcomes, particularly in underrepresented communities, and includes educational resources for patients.
Read more →BBIOBridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418's rapid, consistent treatment effect and favorable saf
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for its oral treatment BBP-418, targeting individuals with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This NDA includes promising interim data from the Phase 3 FORTIFY study, which demonstrated statistically significant and clinically meaningful treatment effects. If approved, BBP-418 could be the first therapy available for this condition, with a potential launch expected by late 2026 or early 2027. The drug has already received multiple designations from health regulatory agencies, facilitating its expedited review process.
Read more →BBIOBridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
BridgeBio Pharma will present long-term efficacy and safety data from the ATTRibute-CM open-label extension trial at the ACC Annual Scientific Sessions in March 2026. The data highlights the benefits of acoramidis in patients with ATTR-CM, including survival benefits and disease stabilization. Additionally, the company will present findings from real-world surveys and other related studies.
Read more →BBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 20, 2026
BridgeBio Pharma announced the approval of equity grants for 29 new employees, totaling 70,916 shares of common stock. These grants are part of an inducement to attract talent under Nasdaq Listing Rule 5635(c)(4). The shares will vest over time, contingent on continued employment. This move aligns with BridgeBio's mission to develop transformative medicines for genetic conditions.
Read more →BBIOBridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
BridgeBio Pharma announced that it will present additional data from the Phase 3 FORTIFY trial for BBP-418 at the MDA Clinical and Scientific Conference. The interim analysis shows that the trial meets its efficacy endpoints for patients with limb-girdle muscular dystrophy type 2I/R9. The conference will also feature presentations from Yale School of Medicine and several posters discussing various aspects of LGMD2I/R9.
Read more →BBIOBridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
BridgeBio Pharma reported strong financial results for Q4 and full year 2025, with net revenues reaching $154.2 million in Q4 and $502.1 million for the year. The company highlighted the successful commercial launch of Attruby, which saw significant growth in prescriptions. Despite the positive momentum, BridgeBio faced increased operating costs and a substantial net loss for the year.
Read more →BBIOBridgeBio to Participate in March Investor Conferences
BridgeBio Pharma, Inc. has announced its participation in several healthcare investor conferences in March 2026. The company's management team will present at these events, which can be accessed via live webcasts. BridgeBio is committed to developing innovative treatments for genetic conditions, aiming to bridge the gap in drug development for small patient populations.
Read more →BBIOBridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates - $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of n
BridgeBio Pharma reported impressive financial results with $154.2 million in net revenues for Q4 2025 and $502.1 million for the full year, driven primarily by its product, Attruby. The company achieved three positive Phase 3 trial results in a short span of time, demonstrating its effective drug development model. Attruby continues to show strong market performance, while upcoming NDA submissions for additional drugs like BBP-418 and encaleret signal potential future growth. Overall, the company's trajectory suggests it is well-positioned for further success in addressing genetic conditions.
Read more →BBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 17, 2026
BridgeBio Pharma announced the approval of equity grants to 34 new employees, totaling 76,701 shares of common stock. These grants are part of an inducement plan under Nasdaq Listing Rule 5635(c)(4) and are intended to attract talent to the company. The vesting schedule is designed to promote employee retention over time.
Read more →BBIOBridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio Pharma, Inc. will release its fourth quarter and full year 2025 financial results on February 24, 2026, after market close. A conference call will follow at 4:30 pm ET to discuss these results and program updates. The event will be accessible via a live webcast, with a replay available for 30 days.
Read more →BBIOBridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
BridgeBio Pharma announced positive topline results from the PROPEL 3 Phase 3 study of oral infigratinib for children with achondroplasia. The study met its primary endpoint, showing significant improvements in height velocity and body proportionality. The treatment was well tolerated, with no serious adverse events reported. BridgeBio plans to submit regulatory applications in late 2026.
Read more →BBIOCORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced the approval of equity grants to 11 new employees, totaling 31,428 shares of common stock. These grants are part of the company's Amended and Restated 2019 Inducement Equity Plan and are intended to incentivize new hires. The shares will vest over time, reflecting the company's commitment to retaining talent as it focuses on genetic diseases.
Read more →BBIOBridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 -- The transaction is intended to stre
BridgeBio Pharma, Inc. has announced a proposed offering of $550 million in convertible senior notes due 2033 to fund the repayment of existing convertible senior notes due 2027. The initiative aims to strengthen the company's financial standing by extending debt maturity, lowering interest expenses, and potentially reducing stock dilution. Funds from this offering will also be used for general corporate purposes, including possible share repurchases. The successful execution of this offering hinges on market conditions and other factors.
Read more →BBIOBridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
BridgeBio Pharma has announced the pricing of $550 million in convertible senior notes due in 2033. The proceeds will primarily be used to repurchase existing convertible senior notes due in 2027 and for general corporate purposes. The offering is expected to close on January 21, 2026, subject to customary conditions.
Read more →BBIOBridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
BridgeBio Pharma announced a proposed offering of $550 million in convertible senior notes due 2033, aimed at strengthening its balance sheet and repaying existing notes due 2027. The offering is expected to lower interest expenses and reduce shareholder dilution. The company plans to use part of its cash for share repurchases, which may influence stock prices.
Read more →BBIOBridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
BridgeBio Pharma provided significant updates at the J.P. Morgan Healthcare Conference, highlighting strong commercial progress for its drug Attruby, which is becoming the preferred treatment for ATTR-CM. The company plans to submit several New Drug Applications (NDAs) in 2026 based on positive clinical trial results. Additionally, BridgeBio announced a new antibody program aimed at ATTR-CM disease reversal and reported a robust financial position to support its growth.
Read more →BBIO▼ -6.2%on this news
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
BridgeBio Pharma, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Neil Kumar will lead the presentation, highlighting the company's focus on genetic diseases and its innovative pipeline. A live webcast will be available, with a replay accessible for 30 days post-event.
Read more →BBIO▼ -6.2%on this newsshared move
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
BridgeBio Pharma will host an investor webinar on January 9, 2026, featuring Dr. Janet Legare, who will discuss achondroplasia and the Phase 3 PROPEL 3 study of infigratinib. The webinar aims to address the unmet needs in treating skeletal dysplasia. Topline results from the study are anticipated in Q1 2026.
Read more →BBIOBridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44 th Annual J.P. Morgan Healthcare Conference - Preliminary unaudited Q4 and Full Year 2025 net Attruby product revenue of $146.0 mill
BridgeBio Pharma announced its commercial progress and program updates at the J.P. Morgan Healthcare Conference, highlighting preliminary Q4 revenue of $146 million for its drug Attruby. The therapy is rapidly gaining traction as the preferred treatment for ATTR-CM, and the company plans to submit NDA filings for various therapies in 2026. Additionally, BridgeBio is advancing multiple pipeline projects, indicating robust growth and expansion in addressing genetic diseases. Overall, the company maintains a strong financial position to support its initiatives moving forward.
Read more →BBIOBridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Read more →BBIOBridgeBio to Participate in December Investor Conferences
BridgeBio Pharma, Inc. has announced its participation in two upcoming healthcare investor conferences in December 2025. The management team will engage in fireside chats at the Piper Sandler Healthcare Conference in New York and the EvercoreISI HealthCONx Conference in Miami. Investors can access live webcasts of these events, along with replays available on the company's website for 90 days afterward. This participation underscores BridgeBio's commitment to transparency and investor engagement.
Read more →BBIOAcoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
BridgeBio Pharma's acoramidis has demonstrated a significant reduction in all-cause mortality among patients with variant ATTR-CM, particularly in the V142I subpopulation. The results, presented at the AHA Scientific Sessions and published in JAMA Cardiology, indicate a 69% decrease in mortality risk. This marks a critical advancement in treatment for a population with previously limited options.
Read more →BBIOBridgeBio to Participate in November Investor Conferences
BridgeBio Pharma, Inc. has announced its participation in several healthcare investor conferences in November. Members of its management team will host fireside chats, allowing investors to engage with the company. The webcasts will be available live and can be replayed for 90 days post-event. BridgeBio focuses on developing transformative medicines for genetic diseases.
Read more →BBIOBridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
BridgeBio Pharma will present ten moderated digital posters at the AHA Scientific Sessions 2025, showcasing findings from the ATTRibute-CM study. Key presentations will highlight the effects of Acoramidis on all-cause mortality and cardiovascular hospitalizations in patients with transthyretin amyloid cardiomyopathy. The event will take place from November 7-10, 2025, in New Orleans, LA.
Read more →BBIOBridgeBio Pharma Reports Third Quarter 2025 Financial Results And Business Update
BridgeBio Pharma Reports Third Quarter 2025 Financial Results And Business Update
Read more →BBIOBridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
BridgeBio Pharma reported strong financial results for Q3 2025, with revenues of $120.7 million driven primarily by the commercial success of its product, Attruby. The company has seen over 5,200 prescriptions written since its FDA approval in November 2024. Despite the positive commercial momentum, BridgeBio also faced increased operating costs and a significant net loss for the quarter.
Read more →BBIOBridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
BridgeBio Pharma announced positive topline results from the Phase 3 CALIBRATE study of encaleret for patients with autosomal dominant hypocalcemia type 1 (ADH1). The study met all primary and key secondary efficacy endpoints, showing significant improvements in calcium and parathyroid hormone levels. The company plans to submit a New Drug Application to the FDA in the first half of 2026.
Read more →BBIOBridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
BridgeBio Pharma, Inc. will announce topline results from the Phase 3 CALIBRATE trial for autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. A conference call will follow to discuss the findings. This event highlights the company's commitment to advancing treatments for genetic diseases.
Read more →BBIO▲ +17.1%on this newsshared move
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
BridgeBio Pharma reported positive results from its Phase 3 FORTIFY study of BBP-418 for LGMD2I/R9, achieving all primary and secondary endpoints. The treatment demonstrated significant improvements in glycosylated alpha-dystroglycan levels and reduced muscle damage markers. The company plans to submit a New Drug Application to the FDA in 2026, aiming to be the first approved therapy for this condition.
Read more →BBIO▲ +17.1%on this newsshared move
BridgeBio Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within
BridgeBio Pharma has announced positive results from its Phase 3 FORTIFY study of BBP-418, an investigational treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The study achieved all primary and secondary endpoints with significant improvements in glycosylated DG levels and muscle damage markers. The company plans to file a New Drug Application with the FDA in the first half of 2026, aiming for BBP-418 to potentially be the first therapy to alter the disease's progression. The study underscores BridgeBio's focus on developing transformative medicines for genetic diseases.
Read more →BBIO▲ +17.1%on this newsshared move
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates - $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby net product revenue, $4.3 million from royalty reve
BridgeBio Pharma reported a successful third quarter in 2025 with total revenues of $120.7 million, featuring notable growth in sales from its product Attruby. The company highlighted positive interim results from ongoing Phase 3 studies for BBP-418 and encaleret, indicating both medications meet crucial efficacy endpoints. The commercial performance signals strong adoption among prescribers, with an increase in unique patient prescriptions. BridgeBio's financial position remains robust with over $645 million in cash, supporting their future growth and expansion in genetic medicine.
Read more →BBIOBridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
BridgeBio Pharma, Inc. will host business update calls to report results from the FORTIFY Phase 3 study for its small molecule BBP-418 targeting Limb-girdle Muscular Dystrophy Type 2I/R9. The interim analysis results webinar is scheduled for October 27, followed by the Q3 2025 earnings report on October 29. These events highlight the company's ongoing commitment to addressing genetic diseases and keeping stakeholders informed.
Read more →BBIOAcoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
BridgeBio Pharma's acoramidis has demonstrated a significant reduction in cumulative cardiovascular outcomes in patients with ATTR-CM, showing a 49% hazard reduction in cardiovascular mortality and hospitalizations compared to placebo. The results, presented at the HFSA Annual Scientific Meeting, indicate that benefits can be observed as early as one month into treatment. Acoramidis is already approved in multiple regions for treating this condition.
Read more →BBIOBridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
BridgeBio Pharma will present several studies related to Acoramidis at the HFSA Annual Scientific Meeting 2025, focusing on its effects on cardiovascular outcomes in patients with ATTR-CM. Key presentations will include findings on mortality rates and hospitalization reductions attributed to Acoramidis. Although the results are promising, some mild adverse effects were reported during trials, which were similar to those seen in placebo groups. This meeting provides a vital platform for disseminating these findings to the scientific and medical community.
Read more →BBIOBridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
BridgeBio Pharma is set to host an investor webinar on September 10, 2025, focusing on autosomal dominant hypocalcemia type 1 (ADH1). Dr. Rachel Gafni from the NIH will discuss the disease's pathophysiology and the ongoing Phase 3 CALIBRATE clinical trial, which is currently evaluating the treatment encaleret. The webinar aims to address current unmet needs in ADH1 and expectations surrounding the clinical study's topline results expected later this year.
Read more →BBIOBridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
BridgeBio Pharma, Inc. has announced that it will present Phase 2 proof-of-concept data for its drug Encaleret, aimed at treating post-surgical hypoparathyroidism, during the ASBMR Annual Meeting 2025 in Seattle. The presentation is scheduled for September 6 and is expected to highlight the drug's effect on reducing urinary calcium while maintaining blood calcium levels. Additionally, the company will present research findings on skeletal dysplasia treatments through poster sessions. This event marks a significant moment for BridgeBio as it showcases advancements in genetic disease therapeutics.
Read more →BBIOBridgeBio to Participate in September Investor Conferences
BridgeBio Pharma, Inc. has announced participation in several upcoming healthcare investor conferences in September. The company will hold fireside chats at the Wells Fargo, Cantor Global, and Morgan Stanley conferences. These presentations will allow management to engage with investors, highlighting BridgeBio's focus on genetic diseases. Additionally, live webcasts will be available for all presentations, with replays accessible for 90 days.
Read more →BBIOBridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
BridgeBio Pharma has announced that it will present additional data from the ATTRibute-CM study at the upcoming ESC Congress 2025 in Madrid. The presentations will include findings on the effectiveness of Attruby in reducing cardiovascular mortality in ATTR-CM patients, with specific details shared in rapid-fire presentations and ePosters. Despite the positive data, some adverse reactions have been noted among patients treated with Attruby, although these were generally mild and manageable.
Read more →BBIOBridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
BridgeBio Pharma reported its second quarter 2025 financial results with total revenue of $110.6 million, largely driven by the strong performance of their drug Attruby® after FDA approval. The drug has shown promising clinical outcomes for patients with ATTR-CM, especially in variant cases, and has achieved a notable increase in prescription rates. The company also highlighted the completion of key Phase 3 study enrollments for other therapies, with topline results anticipated in the near future, indicating a solid extension of their therapeutic portfolio. The company ended the quarter well-capitalized with $756.9 million in cash.
Read more →BBIOBridgeBio Pharma Reports Second Quarter 2025 Financial Results And Business Update
BridgeBio Pharma Reports Second Quarter 2025 Financial Results And Business Update
Read more →BBIOBridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - As of
BridgeBio has reported strong financial results for the second quarter of 2025, with total revenue reaching $110.6 million, primarily driven by the successful launch of its product Attruby. The company noted an increase in prescriptions, reaching 3,751 from 1,074 unique prescribers. Clinical studies showed promising results for Attruby in treating ATTR-CM, reinforcing its position in the market as potentially best-in-class. Looking ahead, key Phase 3 clinical trial results for several therapies are expected in the upcoming months, seeking to further solidify the company’s role in the genetic disease sector.
Read more →BBIOBridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
BridgeBio Pharma, Inc. has announced that it will release its financial results for the second quarter of 2025 on August 5, 2025, after market close. A conference call to discuss these results and provide business updates is scheduled for the same day at 4:30 pm ET. Investors will be able to access the live webcast on the company's website, with a replay available for 30 days following the event.
Read more →BBIOBridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty
BridgeBio Pharma has raised $300 million through a royalty monetization agreement, which allows it to capture capital without significant dilution. This arrangement involves the monetization of 60% of its European royalties from the drug BEYONTTRA, providing immediate funding for the company’s ongoing programs. Acoramidis, marketed as Attruby in the U.S., has shown strong clinical efficacy in treating ATTR-CM, with favorable data from Phase 3 studies. This financial boost is expected to support BridgeBio's product launches and further development of its genetic medicine pipeline.
Read more →BBIOBridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
BridgeBio Pharma, Inc. will host an investor webinar on July 11, 2025, featuring Dr. Matthew Wicklund, who will discuss limb-girdle muscular dystrophy type 2I/R9. The session will highlight the burden of the disease, current standards of care, and ongoing research efforts. Additionally, members of the LGMD2I/R9 program will provide updates on the development of BBP-418 and expectations for Phase 3 interim analysis results in late 2025. The event aims to enhance investor understanding and engagement with BridgeBio's initiatives.
Read more →BBIOBridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
BridgeBio Pharma, Inc. has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025, set to occur on June 9 in Miami, FL. Members of the management team will engage in a fireside chat during the event, allowing them to discuss the company's focus on genetic diseases. Interested parties can access a live webcast of the presentation through BridgeBio's investor section, with a replay available for 30 days afterward.
Read more →BBIOBridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
BridgeBio Pharma plans to present multiple findings from the ATTRibute-CM study at the upcoming Heart Failure Congress in Belgrade. These presentations will cover the clinical outcomes and quality of life improvements associated with acoramidis for treating ATTR-CM. Additionally, data indicating a reduced incidence of atrial fibrillation events in patients treated with acoramidis will also be presented, highlighting its potential benefits. However, some adverse effects have been reported with the treatment, including gastrointestinal issues.
Read more →BBIOBridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
BridgeBio Pharma, Inc. announced its participation in the Bank of America Merrill Lynch Global Healthcare Conference 2025, where members of its management team will engage in a fireside chat. This event is scheduled for May 14 in Las Vegas, and the presentation will be accessible via a live webcast. A replay of the webcast will also be available for 30 days on the company's website, allowing broader access to the company's insights.
Read more →BBIOBridgeBio Pharma Reports First Quarter 2025 Financial Results And Business Update
BridgeBio Pharma Reports First Quarter 2025 Financial Results And Business Update
Read more →BBIOBridgeBio Reports First Quarter 2025 Financial Results and Business Updates
BridgeBio Pharma reported its financial results for Q1 2025, highlighting $36.7 million in revenue from Attruby, which saw significant uptake with 2,072 prescriptions from 756 prescribers. The company successfully completed enrollment for the Phase 2 trial in hypochondroplasia ahead of schedule and initiated dosing for participants. Additionally, a proof-of-principle study for encaleret showed promising results in hypoparathyroidism, with 78% of participants achieving normal calcium levels within days. Overall, the company is well-positioned in its pipeline with multiple late-stage programs advancing toward regulatory milestones.
Read more →BBIOBridgeBio Reports First Quarter 2025 Financial Results and Business Updates - $36.7 million in first full quarter of U.S. Attruby net product revenue and as of
BridgeBio Pharma reported strong financial results for the first quarter of 2025, with $36.7 million in revenue from the commercial launch of Attruby and a promising pipeline update. The company highlighted rapid enrollment in its hypochondroplasia Phase 2 trial and successful proof-of-principle data for encaleret in hypoparathyroidism. Additionally, BridgeBio has a substantial cash reserve of $540.6 million to support its ongoing projects and anticipated milestone payments. The firm anticipates continued success with its therapies and upcoming regulatory approvals, positioning itself as a leader in genetic disease treatment.
Read more →BBIOBridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
BridgeBio Pharma, Inc. has announced that it will release its first quarter financial results for 2025 on April 29, following market closure. The company will host a conference call at 4:30 PM ET to discuss these results and related program updates. Investors can access the presentation through the BridgeBio website, with a replay available for 30 days post-event. This marks a key opportunity for stakeholders to engage with the company's financial performance and future direction.
Read more →BBIO▲ +7%on this news
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
BridgeBio Pharma announced that they will present cardiovascular outcomes data from their Phase 3 ATTRibute-CM study at the upcoming ACC Annual Scientific Sessions. The data involves the performance of acoramidis in patients with both wild-type and variant forms of transthyretin amyloid cardiomyopathy (ATTR-CM). The event is scheduled for March 29-31, 2025, and will include multiple poster presentations related to their findings. The drug, Attruby™, has shown to improve serum TTR levels and is designed to reduce cardiovascular-related issues in patients.
Read more →BBIOBridgeBio Announces CFO Succession
BridgeBio Pharma, Inc. has announced the appointment of Thomas Trimarchi, Ph.D., as the new President and Chief Financial Officer (CFO). Trimarchi, who previously served as Principal Financial Officer, will oversee the company's financial planning and accounting. Brian Stephenson, Ph.D., is leaving the company for personal reasons but will continue to consult. The transition is part of BridgeBio's ongoing strategy to support its mission in the genetic disease space.
Read more →BBIOBridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
BridgeBio Pharma, Inc. has announced the pricing of $500 million in 1.75% convertible senior notes due in 2031. The offering aims to refinance the company's term debt facility, significantly reducing interest expenses and amortization payments. Additionally, the company plans to use part of the proceeds for share repurchases and to enhance operational flexibility. The sale is expected to close on February 28, 2025, subject to standard closing conditions.
Read more →BBIOBridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt - Long term debt management strategy will strengthen the balance sheet w
BridgeBio Pharma has announced a proposed offering of $500 million in convertible senior notes due 2031 to refinance its senior secured debt. The company's strategy aims to strengthen its balance sheet without increasing total liabilities and to lower interest expenses while extending debt maturity. Proceeds from the offering will be used to repay existing borrowings and may also facilitate share repurchases. The final terms of the notes will be disclosed at the pricing of the offering.
Read more →BBIOBridgeBio Pharma Reports Fourth Quarter And Full Year 2024 Financial Results And Commercial Update
BridgeBio Pharma Reports Fourth Quarter And Full Year 2024 Financial Results And Commercial Update
Read more →BBIOBridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - As of
BridgeBio Pharma has reported positive financial results for the fourth quarter and full year 2024, highlighted by the successful launch of Attruby (acoramidis), the first near-complete TTR stabilizer approved for treatment of ATTR-CM. The company noted over 1,028 prescriptions written by 516 prescribers since FDA approval, showcasing strong market adoption. Acoramidis has also achieved significant clinical outcomes, including a 59% hazard reduction in mortality and hospitalizations. Financially, BridgeBio holds $681 million in cash, positioning it well for future operations and regulatory milestones in 2025.
Read more →BBIOBridgeBio Pharma To Report Fourth Quarter And Full Year 2024 Financial Results And Business Update
BridgeBio Pharma To Report Fourth Quarter And Full Year 2024 Financial Results And Business Update
Read more →BBIOBEYONTTRA (acoramidis), The First Near Complete TTR Stabilizer (≥90%), Approved By The European Commission For ATTR-CM
BEYONTTRA (acoramidis), The First Near Complete TTR Stabilizer (≥90%), Approved By The European Commission For ATTR-CM
Read more →BBIO▲ +16%on this news
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and com
BridgeBio Pharma has announced significant commercial progress following the FDA approval of its treatment Attruby (acoramidis), which has generated 430 prescriptions by 248 healthcare professionals since its launch. The company has also completed enrollment for three Phase 3 clinical trials targeting genetic diseases. With a strong financial position, BridgeBio anticipates key regulatory milestones in 2025 and remains focused on delivering transformative medicines for genetic diseases. Despite initial success, some patients experienced mild adverse reactions, and there are ongoing risks related to pending approvals in international markets.
Read more →BBIOBridgeBio Pharma To Participate In The J.P. Morgan Healthcare Conference
BridgeBio Pharma To Participate In The J.P. Morgan Healthcare Conference
Read more →BBIOAttruby (acoramidis), a Near Complete TTR Stabilizer ( 90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients - Attruby is the first and only approved product
Attruby (acoramidis), developed by BridgeBio Pharma, has been approved by the FDA for treating adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This approval marks Attruby as the first drug to achieve near-complete stabilization of transthyretin (TTR). The Phase 3 study demonstrated significant reductions in cardiovascular death and related hospitalizations, with notable benefits observed as early as three months post-treatment. In addition, BridgeBio is implementing Patient Support Services to assist those prescribed Attruby.
Read more →BBIO▼ -5.8%on this news
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
BridgeBio Pharma announced positive results from the PROPEL 2 study of infigratinib for children with achondroplasia, published in the New England Journal of Medicine. The study's Cohort 5 demonstrated significant increases in height velocity and body proportionality over 18 months. Infigratinib has received various FDA designations indicating its potential as a treatment option. Furthermore, the ongoing Phase 3 trial, PROPEL 3, continues to enroll participants, targeting completion by the end of 2024.
Read more →BBIO▼ -5.7%on this news
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - Patients on acoramidis, a near complete ( ≥ 90%) TTR stabilizer in clinical development, lived longer and better as shown in the
BridgeBio Pharma reported strong third-quarter results, highlighting the success of acoramidis as a near complete TTR stabilizer that improved outcomes in patients with ATTR-CM. The company is progressing through its late-stage pipeline with three Phase 3 trials expected in 2025, including the recent completion of trials for encaleret and BBP-418. Regulatory designations, such as Breakthrough Therapy, were granted for infigratinib, supporting their innovative therapies. BridgeBio's financial position remains robust, with expectations of significant milestone payments and a cash reserve of $406 million.
Read more →BBIOBridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
BridgeBio Pharma, Inc. announced the publication of a case study in The Journal of Portfolio Management, exploring the application of portfolio theory in the biopharmaceutical industry. Co-authored by company executives and MIT Professor Andrew W. Lo, the study highlights how BridgeBio's unique portfolio approach enhances early-stage research for genetic diseases. By diversifying research investments, the company aims to de-risk projects and potentially speed up treatment development for patients. The publication commemorates the journal's 50th anniversary, noting the significance of modern finance in biomedical innovation.
Read more →BBIOBridgeBio Pharma Reports Third Quarter 2024 Financial Results And Business Update
BridgeBio Pharma Reports Third Quarter 2024 Financial Results And Business Update
Read more →BBIOBridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
BridgeBio Pharma presented positive data from the CANaspire Phase 1/2 study of BBP-812, a gene therapy for Canavan disease, at the ESGCT 2024 congress. The trial demonstrated significant improvements in motor functions among pediatric participants, showing that some children achieved milestones typical for their ages post-treatment. Additionally, reductions in N-acetylaspartate (NAA) levels in various bodily fluids were observed, indicating potential efficacy. The therapy, if approved, could represent the first viable treatment option for this severe neurodevelopmental disorder.
Read more →BBIOBridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
BridgeBio Pharma, Inc. announced that it will present outcomes data from the ongoing open-label extension of its Phase 3 study of acoramidis for the treatment of ATTR-CM at the upcoming AHA Scientific Sessions in November 2024. The data, which includes results showing reduced all-cause mortality and cardiovascular-related hospitalizations, will be featured in an oral presentation. Additionally, three posters on various aspects of ATTR-CM will be presented during moderated poster sessions at the conference.
Read more →BBIOBridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
BridgeBio Pharma announced the successful completion of enrollment for the FORTIFY Phase 3 study of BBP-418, which targets Limb-girdle Muscular Dystrophy Type 2I/R9. The study not only exceeded its enrollment goals but also plans to utilize a surrogate endpoint for potential Accelerated Approval by the FDA. With positive interim analysis data expected in 2025, BBP-418 may become the first therapy approved for this genetic disorder in the U.S. This announcement coincided with the 10th LGMD Awareness Day, emphasizing the need for effective treatment options.
Read more →BBIOBridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
BridgeBio Pharma presented promising results from the Phase 3 ATTRibute-CM trial of acoramidis at the HFSA Annual Scientific Meeting 2024. The treatment achieved a significant 42% reduction in all-cause mortality and recurrent cardiovascular hospitalizations at 30 months compared to placebo. Additionally, no mortality events were recorded in a parallel study conducted in Japan. Based on the success of the trial, BridgeBio has submitted applications for regulatory approval for acoramidis in both the U.S. and Europe, anticipating positive outcomes in 2024 and 2025.
Read more →BBIOBridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
BridgeBio Pharma, Inc. has announced that the FDA has granted Breakthrough Therapy Designation to its investigational drug infigratinib for treating children with achondroplasia. This designation is based on promising data from the PROPEL 2 clinical trial, which indicated significant improvements in annualized height velocity. If approved, infigratinib could be a first-in-class oral therapeutic option, offering new hope for affected families. The company plans to expedite development and regulatory review leveraging this designation.
Read more →BBIOBridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) - Increase in endogenous cortisol production achieved in all patients in higher dose
BridgeBio Pharma has announced topline results from its Phase 1/2 trial for BBP-631, a gene therapy intended for congenital adrenal hyperplasia (CAH). The trial achieved an increase in cortisol production in all higher dose patients and was well tolerated, with no serious adverse events reported. Despite these advancements, the company decided not to pursue further investment in BBP-631 for CAH, opting to reduce the gene therapy budget by over $50 million and seek partnership opportunities for future development. This decision reflects the ongoing challenges faced in developing therapies for genetic disorders.
Read more →BBIOBridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
BridgeBio Pharma, Inc. has been awarded the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy BBP-812, aimed at treating Canavan disease. This designation is based on promising preliminary results from the CANaspire Phase 1/2 clinical trial, which demonstrated functional improvements among all dosed patients. If approved, BBP-812 may become a groundbreaking treatment for this ultra-rare and fatal disorder, offering hope to affected children and their families. The company will utilize the RMAT designation to facilitate faster regulatory interactions and establish an Accelerated Approval pathway.
Read more →BBIO▲ +13.1%on this news· ran to +27% by day 3
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
BridgeBio Pharma presented positive data at the ESC 2024 regarding acoramidis, which showed a significant increase in serum transthyretin (TTR) levels among patients transitioning from tafamidis or placebo. The findings indicated a correlation between elevated TTR levels and reduced risks of all-cause and cardiovascular mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Following this promising data, BridgeBio has submitted a New Drug Application to the FDA, with plans for marketing in Europe in collaboration with Bayer.
Read more →BBIOBridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
BridgeBio Pharma, Inc. will present additional analyses from its Phase 3 ATTRibute-CM trial of acoramidis for treating transthyretin amyloid cardiomyopathy (ATTR-CM) at two significant conferences: the ESC Congress 2024 in London and the HFSA Annual Meeting 2024 in Atlanta. The presentations will include insights on serum TTR levels and clinical outcomes. Notable speakers from prestigious institutions will present the findings, highlighting the company's commitment to addressing genetic diseases.
Read more →BBIOBridgeBio Pharma to Participate in September Investor Events
BridgeBio Pharma, a biopharmaceutical firm focused on genetic diseases, has announced its upcoming participation in several investor conferences. Notable events include the Morgan Stanley 22nd Annual Global Health Care Conference and the Wells Fargo 19th Annual Healthcare Conference, slated for September 4th and 5th, respectively. The company will also present at the Cantor Global Healthcare Conference on September 17th. Webcasts of these presentations will be accessible through their website.
Read more →BBIOBridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
BridgeBio Pharma has partnered with the CarDS Lab to launch the TRACE-AI Network Study aimed at improving the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). This initiative utilizes advanced artificial intelligence tools to identify undiagnosed cases earlier, focusing on diverse patient demographics. The project will analyze health records from various sites to quantify the prevalence of ATTR-CM and evaluate its risks. This collaboration seeks to enhance diagnostic practices within healthcare systems and improve patient outcomes.
Read more →BBIOBridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
BridgeBio Pharma announced the launch of MyAchonJourney, an online resource for families dealing with achondroplasia. This initiative aims to provide medical information, psychosocial support, and practical guidance to help families navigate challenges from pregnancy through young adulthood. Developed in collaboration with community leaders, MyAchonJourney seeks to empower individuals and promote awareness about living with achondroplasia. Future plans include additional phases to cater to older children and young adults.
Read more →BBIOBridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update - Acoramidis demonstrated a significant impact on mortality, hospitalizations, and quality of life - Starting at Month 3, patients taking
BridgeBio Pharma reported strong financial results for Q2 2024, highlighting acoramidis's significant effects on mortality and quality of life. The company is progressing well in its clinical trials, surpassing enrollment targets for key studies while maintaining a solid cash position of $587 million. Acoramidis showed a 42% reduction in adverse cardiac events compared to placebo after 30 months. The company is on target to launch acoramidis commercially and has milestones expected in 2025 for multiple ongoing studies.
Read more →BBIOBridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
BridgeBio Pharma, Inc. has appointed Thomas Trimarchi, Ph.D., as President and Chief Operating Officer, effective immediately. Dr. Trimarchi joins the company from the role of Chief Product Officer and brings significant experience from previous positions at Regeneron and Goldman Sachs. He will focus on enhancing operational excellence and strategic planning within the organization. The company's CEO, Neil Kumar, expressed confidence in Dr. Trimarchi's leadership and dedication to serving patients with genetic diseases.
Read more →BBIOBridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
BridgeBio Pharma has successfully exceeded its interim enrollment target for the Phase 3 FORTIFY study, which focuses on the investigational treatment BBP-418 for Limb-girdle Muscular Dystrophy Type 2I/R9. The FDA has designated BBP-418 as a Rare Pediatric Disease, potentially allowing for a Priority Review Voucher if approved. The company aims to demonstrate the drug's efficacy through ongoing trials, with top-line results expected in 2025. Additionally, positive interactions with the FDA bolster BridgeBio's plans for Accelerated Approval based on promising preliminary data.
Read more →BBIOBridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
BridgeBio Pharma will present at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024. CEO Neil Kumar will represent the company during this esteemed event held in Miami, FL. Investors can access a live webcast of the presentation, which will also be available for replay for 90 days post-event.
Read more →BBIO▼ -6.4%on this newsshared move
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia - In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral
BridgeBio announced that infigratinib has shown durable results in its Phase 2 trial for achondroplasia, demonstrating significant improvements in growth velocity and body proportions at 12 and 18 months. The positive outcomes support further development in hypochondroplasia, where the first participant has already been consented for an observational study. The ongoing PROPEL 3 study continues on schedule, and results indicate that infigratinib has the potential to enhance functionality for affected children.
Read more →BBIOBridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
BridgeBio Pharma, Inc. is set to host a call on June 4, 2024, to discuss results from Month 12 and Month 18 of Cohort 5 of the PROPEL 2 Phase 2 trial. The study focuses on the investigational oral therapy infigratinib for treating achondroplasia in children. Dr. Ravi Savarirayan from Murdoch Children's Research Institute will be among the presenters, highlighting the collaboration with leading experts in the field. A replay of the call will be available for 90 days post-event.
Read more →BBIOBridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1)
BridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Read more →BBIOBridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
BridgeBio Pharma is set to present significant findings from the Phase 3 ATTRibute-CM study of Acoramidis at the 2024 International Symposium on Amyloidosis in Rochester, Minnesota. The company is hosting an investor call on May 29, 2024, to discuss recent analyses and the impact of Acoramidis on patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Key presentations will include insights on clinical outcomes, quality of life improvements, and biomarker effects from the trial.
Read more →BBIOBridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BridgeBio Pharma, a biopharmaceutical company specializing in genetic diseases and cancers, has announced its participation in the Bank of America Merrill Lynch Global Healthcare Conference 2024. The presentation is scheduled for May 15 at 3:00 pm PT in Las Vegas, NV. Interested parties can access a live webcast of the event, with a replay available on BridgeBio's website for 90 days thereafter.
Read more →BBIOBridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
BridgeBio Pharma presented promising results from its Phase 3 ATTRibute-CM study at the ESC Heart Failure Congress 2024. Treatment with acoramidis demonstrated a significant reduction in all-cause mortality among participants, alongside improvements in health-related quality of life metrics. The study included high-risk patients with Stage 4 chronic kidney disease, showing no safety concerns. Following positive outcomes, BridgeBio has submitted regulatory applications for approval of acoramidis for ATTR-CM treatment.
Read more →BBIOBridgeBio Pharma Reports First Quarter 2024 Financial Results And Business Update
BridgeBio Pharma Reports First Quarter 2024 Financial Results And Business Update
Read more →BBIOBridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
BridgeBio Pharma, Inc. has successfully completed a $200M private financing for its subsidiary, BridgeBio Oncology Therapeutics (BBOT), aimed at accelerating its precision oncology pipeline. BBOT plans to advance three key programs targeting various RAS and PI3Kα pathway malignancies, with significant clinical milestones expected in the next 18-24 months. The new funding was obtained through participation from leading investors, which will also support ongoing research in targeting additional oncogenic drivers. Dr. Eli Wallace has been appointed CEO, signaling a robust leadership strategy for the success of BBOT's initiatives.
Read more →BBIOBridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update - Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin
BridgeBio Pharma reported strong first quarter 2024 financial results, including clinical advancements in treatments for transthyretin amyloid cardiomyopathy and limb-girdle muscular dystrophy. The company presented cardiac magnetic resonance imaging evidence supporting clinical improvements in ATTR-CM patients and is preparing for upcoming medical meetings to share further data. Additional capital raised will support the launch of a new oncology division and the ongoing trials for its pipeline candidates, with significant license agreements contributing to revenue growth.
Read more →BBIOBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma has presented results from an exploratory CMR imaging substudy showing that acoramidis may lead to cardiac improvement in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This substudy builds on positive results from the ATTRibute-CM Phase 3 trial, which demonstrated a significant clinical benefit associated with the drug. The U.S. FDA has accepted the New Drug Application for acoramidis, and a decision from the EMA is expected in 2025. Researchers observed no safety concerns, reinforcing the drug's promising profile in treating ATTR-CM.
Read more →BBIOBridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Read more →BBIOBridgeBio Pharma Announces Pricing of Public Offering of Common Stock
BridgeBio Pharma announced the pricing of its underwritten public offering of 8,620,690 shares of common stock at $29.00 per share, expected to raise about $250 million. The offering will close on or about March 8, 2024, subject to customary closing conditions. J.P. Morgan and Cantor are acting as joint book-running managers for the offering. However, uncertainties regarding market conditions and completion terms pose risks to the anticipated fundraising.
Read more →BBIO▼ -9.2%on this newsshared move
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
BridgeBio Pharma has announced a proposed public offering of common stock to raise $250 million, with the potential for underwriters to purchase an additional $37.5 million in shares. The offering is contingent upon market conditions and no guarantees can be made regarding its completion or final terms. J.P. Morgan, Cantor Fitzgerald & Co., and Mizuho are among the joint managers handling the offering. The securities will be offered under an existing shelf registration statement previously filed with the SEC.
Read more →BBIO▼ -9.2%on this newsshared move
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BridgeBio Pharma has entered a licensing agreement with Bayer for the commercialization of acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), in Europe. As part of the agreement, BridgeBio will receive up to $310 million in payments along with royalties starting in the low-thirties percent. Acoramidis's FDA New Drug Application has been accepted, with a decision expected by November 29, 2024, and the EMA has also accepted its Marketing Authorization Application with potential approval in 2025. This partnership aims to utilize Bayer's expertise to expedite the availability of acoramidis for patients.
Read more →BBIOBridgeBio Pharma Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
BridgeBio Pharma Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
Read more →BBIOBridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update - Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transth
BridgeBio Pharma reported its fourth quarter and full year 2023 financial results, highlighting the submission of a New Drug Application for acoramidis to the FDA. The NDA is based on positive results from the Phase 3 ATTRibute-CM trial, and the application has been accepted for review. Additionally, the company secured up to $1.25 billion in capital, which includes a significant upfront payment from Kyowa Kirin for infigratinib licensing. The financial results showed a decrease in revenue and cash position due to operating expenses.
Read more →BBIOBridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
BridgeBio Pharma has announced a partnership with Kyowa Kirin, granting the latter an exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan. The agreement includes a robust upfront payment of $100 million and potential royalties on future sales. Infigratinib, currently in clinical trials, has shown promising results for treating achondroplasia, with ongoing studies aimed at evaluating its efficacy in children. This collaboration is expected to enhance access to treatment options for patients in Japan.
Read more →BBIOBridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma announced the FDA's acceptance of their New Drug Application for acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), with a PDUFA action date set for November 29, 2024. Positive results from the Phase 3 ATTRibute-CM study indicated a significant survival rate and low hospitalization frequency among patients receiving acoramidis. The company is also preparing additional global regulatory submissions after the European Medicines Agency accepted the Marketing Authorization Application.
Read more →BBIOBridgeBio Pharma Shares Positive Results Of Single-arm Phase 3 Study Of Acoramidis In Japanese Patients With ATTR-CM
BridgeBio Pharma Shares Positive Results Of Single-arm Phase 3 Study Of Acoramidis In Japanese Patients With ATTR-CM
Read more →BBIOBridgeBio Pharma Secures Up To $1.25 Billion Of Capital From Blue Owl And CPP Investments To Accelerate Commercial Launch
BridgeBio Pharma Secures Up To $1.25 Billion Of Capital From Blue Owl And CPP Investments To Accelerate Commercial Launch
Read more →BBIOBridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine
BridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine
Read more →BBIOJPM Presentation 2024 Forward-Looking Statement and Disclaimer The presentation may contain forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered
BridgeBio's presentation at the JPM 2024 highlighted its focus on developing therapies for genetic diseases. The company is actively pursuing multiple clinical programs, including acoramidis for transthyretin amyloidosis, with promising indications of significant market potential. BridgeBio aims to capitalize on the unmet needs within the genetic disease sector, projecting billions in sales and a robust pipeline of products. However, the statements made are forward-looking and carry inherent risks and uncertainties regarding clinical success and regulatory approvals.
Read more →BBIO▼ -6.4%on this newsshared move
BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C
BridgeBio Announces FDA Clearance Of IND Application For BBO-8520, A First-in-class Direct Inhibitor Of KRASG12C
Read more →BBIO▲ +5.1%on this news
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
BridgeBio has announced the successful dosing of the first child in the PROPEL 3 clinical trial, which aims to evaluate the effectiveness and safety of infigratinib in treating children with achondroplasia. The trial has received favorable feedback from the FDA and EMA, indicating its design could support a future marketing application. Results from prior Phase 2 trials show infigratinib's potential to improve growth metrics in this patient population. The company is also planning to develop infigratinib for hypochondroplasia, with an observational study set to begin in 2024.
Read more →BBIOBridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma has submitted a New Drug Application (NDA) for its investigational drug acoramidis to the U.S. FDA for treating Transthyretin Amyloid Cardiomyopathy (ATTR-CM). This decision is supported by positive results from the Phase 3 ATTRibute-CM study, which showed significant improvement in survival rates and other health measures. The submission highlights the drug's strong efficacy profile and good tolerability. Additional marketing applications are anticipated for 2024 following this initial submission.
Read more →BBIOBridgeBio Pharma Announces Acoramidis Phase 3 ATTRibute-CM Data Presented At AHA And Published In NEJM
BridgeBio Pharma Announces Acoramidis Phase 3 ATTRibute-CM Data Presented At AHA And Published In NEJM
Read more →BBIOBridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
BridgeBio Pharma has presented favorable additional data from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). The study met its primary endpoint with a significant win ratio and showed early, sustained benefits in reducing mortality and hospitalization rates. The company plans to file a New Drug Application (NDA) with the FDA by the end of 2023, highlighting potential therapeutic advantages of acoramidis over current treatments. Acoramidis has shown promise in improving clinical outcomes, with no identified safety concerns.
Read more →BBIO▼ -7.9%on this newsshared move
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
BridgeBio Pharma, Inc. announced it will present additional Phase 3 data from the ATTRibute-CM study on acoramidis for patients with Transthyretin Amyloid Cardiomyopathy at the AHA Scientific Sessions 2023. The study has demonstrated a highly statistically significant primary endpoint result with a Win Ratio of 1.8 (p<0.0001). As part of the presentation, Dr. Daniel Judge will discuss the improvements in clinical outcomes for patients. An investor call will also follow the presentation to discuss the findings in more detail.
Read more →BBIOBridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update - Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congre
BridgeBio Pharma reported its third quarter 2023 financial results and provided a positive business update. Notably, the company presented encouraging results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology Congress, showing improved survival rates and reduced hospitalizations for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The company plans to file a New Drug Application for acoramidis with the FDA by the end of 2023. They also reported advancements across their pipeline, including regulatory progress for infigratinib and promising data for BBP-418 in limb-girdle muscular dystrophy.
Read more →BBIOBridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma has reported the granting of restricted stock units to nineteen new employees as part of their induction process. This initiative, compliant with Nasdaq Listing Rule 5635(c)(4), involves an aggregate of 227,507 shares of common stock allocated to new hires. The vesting of these shares is structured over several periods, fostering employee retention and aligning their interests with the company’s performance. The Plan under which these awards were granted was initially adopted in 2019 and has been amended in 2023.
Read more →BBIOBridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
BridgeBio Pharma has announced positive proof-of-concept Phase 2b results for its investigational drug, encaleret, in patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1). The study demonstrated that encaleret effectively restored mineral homeostasis, correcting hypocalcemia and reducing hypercalciuria without significant adverse effects. Enrollment in the ongoing Phase 3 CALIBRATE trial is underway, with topline data expected in the first half of 2024. This investigational therapy has the potential to be the first approved treatment specifically for ADH1.
Read more →BBIOBridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
BridgeBio Pharma presented positive long-term data from its ongoing Phase 2 study of BBP-418 for LGMD2I/R9 at the Annual Congress of the World Muscle Society. The data demonstrated a well-tolerated safety profile and stability in ambulatory measures and biomarkers after 21 months of treatment. Notably, early changes in glycosylated αDG levels were linked to subsequent improvements in mobility, supporting their use as a surrogate endpoint for future trials. The company is actively enrolling patients for a Phase 3 study aimed at further validating the therapeutic potential of BBP-418.
Read more →BBIOBridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
BridgeBio Pharma and National Resilience have formed a strategic partnership to manufacture and advance two investigational gene therapies: BBP-631 for congenital adrenal hyperplasia and BBP-812 for Canavan disease. The partnership emphasizes a novel, capital-efficient, and sustainable manufacturing model that allows BridgeBio to expedite the development of its therapies. Resilience will provide in-kind manufacturing services and support ongoing clinical development for these programs. This collaboration is expected to improve access to innovative treatments for patients with significant unmet needs.
Read more →BBIOBridgeBio Pharma Announces $250 Million Private Placement Equity Financing - $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management fi
BridgeBio Pharma has announced a private placement equity financing of $250 million, primarily led by the Qatar Investment Authority. The financing, which involves the sale of approximately 9.17 million shares, aims to fully capitalize the company toward profitability. The funds will be utilized for upcoming operations including the launch of the drug acoramidis and critical Phase 3 trials in several conditions. The transaction will close on September 27, 2023, pending customary conditions.
Read more →BBIOBridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BridgeBio Pharma, a company specializing in genetic diseases and cancers, is set to present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York. The presentation is scheduled for September 12, 2023, at 10:50 am ET. Interested parties can access the live webcast on the company's website, with a replay available for 90 days post-event. This participation underscores BridgeBio's efforts to engage with investors and stakeholders in the healthcare sector.
Read more →BBIOBridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
BridgeBio Pharma has announced that it received positive feedback from the U.S. FDA and the EU EMA concerning its pivotal Phase 3 trial for infigratinib in children with achondroplasia. Both agencies approved the trial's design, allowing initiation by the end of 2023. The trial aims to assess infigratinib's safety and efficacy, with a primary endpoint focusing on height velocity changes. Additionally, the company will explore infigratinib's effects on other related skeletal dysplasias, indicating a broader commitment to addressing unmet medical needs in pediatric patients.
Read more →BBIOBridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
BridgeBio Pharma presented positive results from the Phase 3 ATTRibute-CM study of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) at the European Society of Cardiology Congress 2023. The trial met its primary endpoint with a statistically significant Win Ratio of 1.8 and demonstrated an 81% survival rate, substantially higher than previously reported figures. Patients receiving acoramidis also showed improved measures in disease progression and physical function. The company plans to submit a New Drug Application (NDA) to the FDA by the end of 2023.
Read more →BBIOBridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
BridgeBio Pharma is set to present detailed results from the Phase 3 ATTRibute-CM study focusing on acoramidis for treating transthyretin amyloid cardiomyopathy at the ESC Congress 2023. The study aims to demonstrate the efficacy and safety of acoramidis, a next-generation therapeutic agent. Notably, preliminary results indicate a high level of TTR stabilization in patients, offering a promising alternative to tafamidis. The company will also host a symposium to discuss developments in ATTR-CM treatment options.
Read more →BBIOBridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update - Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardio
BridgeBio Pharma announced positive results for its Phase 3 ATTRibute-CM study of acoramidis, demonstrating a significant impact on key health indicators for patients with transthyretin amyloid cardiomyopathy. The company plans to file a New Drug Application for acoramidis by the end of 2023. Additionally, they presented promising data on infigratinib in children with achondroplasia and initiated a Phase 3 study for BBP-418 in limb girdle muscular dystrophy. Financially, BridgeBio ended the quarter with $353 million, ensuring a solid runway into 2024.
Read more →BBIOBridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
BridgeBio Pharma announced the potential for accelerated approval of BBP-418 for LGMD2I/R9 following discussions with the FDA. The company has dosed the first patient in its Phase 3 FORTIFY trial, which aims to evaluate the safety and efficacy of BBP-418. The trial will feature an interim analysis on glycosylated alpha-dystroglycan levels, with topline results expected in late 2024 or early 2025. This development is significant as there are currently no approved treatments for this rare muscular dystrophy.
Read more →BBIO▲ +75.9%on this news· ran to +89% by day 3shared move
BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study
BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study
Read more →BBIO▲ +75.9%on this news· ran to +89% by day 3shared move
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) - Highly statistically significant result observed on prima
BridgeBio has announced notably positive results from its Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The study showed a highly statistically significant improvement in survival and reduced frequency of hospitalization. The company plans to file a New Drug Application with the FDA by the end of 2023, indicating a strong potential for bringing acoramidis to market.
Read more →BBIO▲ +5.3%on this news· ran to +99% by day 3shared move
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
BridgeBio Pharma is set to host an investor call on July 17, 2023, to present topline results from the Phase 3 ATTRibute-CM study, which focuses on transthyretin amyloid cardiomyopathy. This event signifies the company's commitment to communication with investors and stakeholders regarding its developments in genetic diseases. The results shared during this call are anticipated to provide valuable insights into the effectiveness of their treatment in the study's patient population.
Read more →BBIO▲ +10.1%on this news
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
BridgeBio Pharma presented the updated six-month results from its Phase 2 Cohort 5 trial of infigratinib for achondroplasia at the Endocrine Society 2023 Annual Conference. The therapy showed a significant increase in annual height velocity, with 83% of participants responding positively. Additionally, infigratinib was well-tolerated, with no adverse events recorded. The company is preparing to initiate a Phase 3 trial based on these promising results.
Read more →BBIOBridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
BridgeBio Pharma announced that it will present updated results from its Phase 2 trial of infigratinib at the Endocrine Society 2023 Annual Conference. The presentations will include data on the height velocity of children with achondroplasia and additional findings regarding its other genetic programs. The trial shows promising outcomes, thus highlighting the therapeutic potential of infigratinib in treating genetic disorders.
Read more →BBIOBridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
BridgeBio Pharma presented promising clinical data for its gene therapy BBP-812 aimed at treating Canavan disease at the 2023 ASGCT Annual Meeting. In a Phase 1/2 trial, participants showed significant decreases in N-acetylaspartate (NAA) levels, along with improvements in brain myelination and developmental function. This investigational treatment could potentially represent the first approved therapy for Canavan disease, a severe neurodevelopmental disorder. The results indicate that all trial participants did not lose functional abilities and some showed improvements in key developmental outcomes.
Read more →BBIO▲ +9.6%on this news
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1/2 clinical
Read more →BBIO▼ -6.2%on this news
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update - Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patien
BridgeBio Pharma has reported its financial results for Q1 2023, highlighting the completion of the last patient visit in its Phase 3 ATTRibute-CM trial for acoramidis, with topline data expected by July 2023. The company also revealed positive results from the Phase 2 PROPEL 2 trial of infigratinib in children with achondroplasia, pointing towards strong potential efficacy. Financially, BridgeBio closed a $150 million public offering, bolstering its cash reserves to $467 million. While the company continues to face significant operational losses, steps have been taken to reduce costs.
Read more →BBIOBridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at th
Read more →BBIO▲ +5.8%on this news· ran to +17% by day 3
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO (nivolumab)
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven
Read more →BBIOBridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2I patients - BridgeBio also shared 15-month results from its ongoing Phase 2 stu
Read more →BBIOBridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023 - Preliminary findings and study results will be presented in an
Read more →BBIO▲ +52%on this news· ran to +71% by day 1shared move
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events - In the highest
BridgeBio recently announced promising Phase 2 results for its drug, infigratinib, in treating achondroplasia, showing a mean increase in annualized height velocity of 3.03 cm/year with no adverse treatment-related events. The results, based on a study of children, indicate that 80% were responders, achieving a median height velocity of 7.6 cm/year. These findings signal the potential for infigratinib to significantly improve the growth of children affected by this condition. Following these results, BridgeBio is preparing to initiate a pivotal Phase 3 trial and has plans to explore the drug's effects on hypochondroplasia.
Read more →BBIO▲ +52%on this news· ran to +71% by day 1shared move
BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia
BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia
Read more →BBIOBridgeBio To Host Investor Call To Discuss Phase 2 Cohort 5 Data For Achondroplasia
BridgeBio To Host Investor Call To Discuss Phase 2 Cohort 5 Data For Achondroplasia
Read more →BBIOBridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to hav
BridgeBio Pharma reported its financial results for Q4 and the full year 2022, indicating a continuing focus on several clinical trials, including the Phase 3 ATTRibute-CM trial of acoramidis. The company has a solid financial standing with $466.2 million in cash, which it expects will support its operations into 2024. Despite reduced operating costs resulting from restructuring efforts, substantial operating losses were noted, with a net loss of approximately $484.7 million for the year. Meanwhile, key trial readouts are anticipated in 2023 that may influence future business progress.
Read more →BBIOBridgeBio Pharma To Host Educational Roundtable With Esteemed Achondroplasia Expert
BridgeBio Pharma To Host Educational Roundtable With Esteemed Achondroplasia Expert
Read more →BBIOBridgeBio Pharma To Participate In February And March Investor Events
BridgeBio Pharma To Participate In February And March Investor Events
Read more →BBIO▲ +9.9%on this news
BridgeBio Pharma To Present At The J.P. Morgan Healthcare Conference
BridgeBio Pharma To Present At The J.P. Morgan Healthcare Conference
Read more →BBIOBridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week treatment period in patients with autosomal dominant hypocalcemia ty
Read more →BBIO▼ -8.4%on this news
BridgeBio Pharma to Participate in November Investor Events
PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in
Read more →BBIOBridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update - Reported positive preclinical data for its next-generation KRAS G12C GTP/GDP dual inhibitor development candidate, BBO-8520, and f
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update - Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3K :RAS breaker mechanism in late lead optim
Read more →BBIO▼ -7%on this news
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples Increase in the ratio of glycosylated αDG to total αDG from baseline towards normal levels, suggesting that the investigational oral the
Read more →BBIO▼ -7.4%on this newsshared move
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from the first three participants show sustained reductions in N-acetylaspartate (NAA) in the brain and urine, suggesting that the investigational therapy i
Read more →BBIOBridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS (sotorasib)
- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily dosing in addition to synergistic activity with other agents to treat cancers driven by KRAS G12C mutations - The combination of investi
Read more →BBIOBridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
- The conference will take place at the National Cancer Institute at Frederick, Maryland from October 17-19, 2022 - Presentation to include details from next-generation G12C dual inhibitor clinical candidate and characterization of advanced leads from the PI3Kα:RAS breaker progr
Read more →BBIOBridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY (fosdenopterin) for the Treatment of MoCD Type A
- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years. - European Commission (
Read more →BBIOBridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
- Initial data readout for patients with PA and MMA expected in the first half of 2023 - Interim data from healthy individuals, reported earlier this year, showed that BBP-671 was detected in plasma and cerebrospinal fluid (CSF) at concentrations above predicted therapeutic thre
Read more →BBIO▲ +8.1%on this news
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY (fosdenopterin) for the Treatment of MoCD Type A
- NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years - NULIB
Read more →BBIO▲ +25.7%on this news· ran to +41% by day 1
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update - Reported positive interim Phase 2 data for infigratinib in achondroplasia demonstrating a mean increase in annualized height velo
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update - Reported positive interim Phase 2 data for infigratinib in achondroplasia demonstrating a mean increase in annualized height velocity (AHV) of 1.52 cm/year among all Cohort 4 children 5 y
Read more →BBIO▼ -15.8%on this news
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) was +1.52 cm/yr (p=0.02, n=11) and the responder rate was 64% in children 5 years and older1 - Infigratinib was well-tolerated with
Read more →BBIO▲ +8.7%on this newsshared move
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY (fosdenopterin) for the Treatment of MoCD Type A
- CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is based on the efficacy and safety data collected to date compared to data from a natural history study - Under an accelerate
Read more →BBIOBridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a new collaboration with Baylor College of Medicine to identify and translate cutting-
Read more →BBIOBridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced its founding affiliation with Bakar Labs, the incubator at UC Berkeley’s Bakar BioEngi
Read more →BBIOBridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold increases in plasma glycolate, suggesting it has the potential to be both a best-in-class therapy and the first oral therapy for PH1 and recurrent kidney stone for
Read more →BBIO▲ +6%on this news· ran to +17% by day 3shared move
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease - Initial pharmacodynamic results for two participants show unprecedented decreases in N-acetylaspartate (NAA) in the brain a
Read more →BBIO▼ -10.7%on this news
BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5 of therapy and sustained at 24 weeks, and was well-tolerated without any report
Read more →BBIO▼ -11.1%on this newsshared move
BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations
PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the Phase 1b trial of VT30 topical gel (BBP-681) in patients with venous, lymphatic an
Read more →BBIOBridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
- BridgeBio will host an investor call on June 13, 2022, at 4:30 pm ET to discuss the Phase 2b study results and the planned pivotal Phase 3 study design PALO ALTO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a
Read more →BBIOBridgeBio Pharma to Participate in June Investor Events
PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in
Read more →BBIOBridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
- BBP-671 detected in healthy volunteer plasma and cerebrospinal fluid (CSF), suggesting that BBP-671 is entering the brain, a location critical to target neurological complications of PKAN and organic acidemias at their source - Results showed BBP-671 increased whole blood acet
Read more →BBIOBridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- PTR-01 was well-tolerated over a four-month treatment period in RDEB patients - Treatment with PTR-01 led to rapid, consistent, and durable wound healing as observed in reduction of wound surface area and clinician-reported assessments - All patients that completed the study
Read more →BBIO▲ +10.2%on this newsshared move
BridgeBio Pharma to Participate in May Investor Events
PALO ALTO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in
Read more →BBIO▲ +11.4%on this newsshared move
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years - Entered into a definitive agreement to sell the rare pediatric disease Pri
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two -Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110
Read more →BBIO▲ +14%on this news· ran to +43% by day 3shared move
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology - BridgeBio is eligible to receive up to $905 millio
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology - BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to
Read more →BBIO▲ +6.9%on this news· ran to +17% by day 3shared move
BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference
PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will participate in
Read more →BBIO▲ +6.9%on this news· ran to +17% by day 3shared move
BridgeBio Pharma, Inc. Reports First Quarter 2022 Financial Results And Business Update
BridgeBio Pharma, Inc. Reports First Quarter 2022 Financial Results And Business Update
Read more →BBIO▼ -12.5%on this news· ran to -29% by day 3shared move
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update Completed sale to Sentynl Therapeutics of BridgeBio s NULIBRY (Fosdenopterin) for Injection Updated strategic collaboration with Helsinn G
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update Palo Alto, CA May 5, 2022 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its
Read more →BBIO▲ +10.8%on this news
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBNP was -437 pg/mL with 68% of participants observing NT-proBNP levels below the
Read more →BBIOBridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo
PALO ALTO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that updated data from its ongoing Phase 2 open-label
Read more →BBIOBridgeBio Pharma Announces Positive Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
BridgeBio Pharma Announces Positive Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Read more →BBIOBridgeBio Pharma, Inc. To Host Investor Call To Discuss Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
BridgeBio Pharma, Inc. To Host Investor Call To Discuss Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Read more →BBIOBridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation
BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation
Read more →BBIO▲ +9%on this news
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio s financial runway into 202
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio s financial runway into 2024 Dosed first patient in Phase 1/2 trial of investigation
Read more →BBIO▼ -8.1%on this news
BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia
BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia
Read more →BBIOBridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510
BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510
Read more →BBIO▼ -72%on this news
BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and p
BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study PALO ALTO, CA December 27, 2021 BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced topline results from Month 12 (Part A) of ATTRibute-CM, an ongoing global Phase 3 study investigating acoramid
Read more →BBIOBridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs - BridgeBio and Helsinn have also established a non-exclusive framework agreement to ident
Read more →BBIOBridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing -Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the C
BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing -Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company s 30+ genetic disease and cancer pipeline programs
Read more →BBIOBridgeBio Pharma, Inc. Reports Third Quarter 2021 Financial Results And Business Update
BridgeBio Pharma, Inc. Reports Third Quarter 2021 Financial Results And Business Update
Read more →BBIOBridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update Topline results from Part A of the Phase 3 ATTRibute-CM trial of TTR stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM) expecte
BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update PALO ALTO, Calif., NOVEMBER 4, 2021 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today re
Read more →BBIOBridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors
BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on
Read more →BBIOBridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors PALO ALTO, CA August 18, 2021 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, cre
Read more →BBIOBridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update Received U.S. Food and Drug Administration (FDA) approval for TRUSELTIQ (infigratinib) under the accelerated approval program for p
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update PALO ALTO, Calif., AUGUST 5, 2021 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create, test and delive
Read more →BBIOBridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results And Business Update
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results And Business Update
Read more →BBIOBridgeBio Pharma Announces Topline Results From Phase 3 ATTRibute-CM Study
BridgeBio Pharma Announces Topline Results From Phase 3 ATTRibute-CM Study
Read more →BBIOBridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
PALO ALTO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, t
Read more →BBIOBridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement BridgeBio, through its affiliate QED (“Bri
Read more →BBIOBridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
PALO ALTO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, to
Read more →BBIOBridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update Received U.S. Food and Drug Administration (FDA) approval for NULIBRY (fosdenopterin) for injection as the first therapy to reduce t
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update Received U.S. Food and Drug Administration (FDA) approval for NULIBRY (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor
Read more →BBIOBridgeBio Pharma And LianBio Announce Strategic Collaboration To Develop And Commercialize Innovative Medicines In China And Other Asian Markets
BridgeBio Pharma And LianBio Announce Strategic Collaboration To Develop And Commercialize Innovative Medicines In China And Other Asian Markets
Read more →BBIOBridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
Read more →BBIOBridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers
PALO ALTO, Calif. and BUFFALO, N.Y., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically dri
Read more →BBIOBridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with g
Read more →BBIOBridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients
PALO ALTO, Calif. and PROVIDENCE, R.I., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines fo
Read more →BBIOBridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven dis
Read more →BBIOBridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
PALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patient
Read more →BBIOBridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for
Read more →BBIOBridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research
PALO ALTO, Calif. and EDMONTON, Alberta, April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Excellence, today announced a collaboration to translate scientific research in gl
Read more →BBIOBridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma
BridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma
Read more →BBIOBridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology BridgeBio, through its Affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other i
Read more →BBIOBridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting
– Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept – At Doses up to 180 mg Twice Daily, Encaleret was Well-Tolerated with No Serious Adverse
Read more →BBIOBridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A
BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of Patients With MoCD Type A
Read more →BBIOBridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years Clinical
Read more →BBIOBridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastruc
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update Calif., FEBRUARY 25, 2021 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a clinical-stage biopharmaceutical company founded to discover, create, test and del
Read more →BBIOBridgeBio Pharma Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
BridgeBio Pharma Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
Read more →BBIOBridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today a
Read more →BBIOBridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and aff
Read more →BBIOBridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock
PALO ALTO, Calif. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 shares of its common stock at a price per share of $62.50 by selling stockholde
Read more →BBIObridgebio pharma, inc. announces launch of secondary offering of common stock 11.02.2021 at 4:10
bridgebio pharma, inc. announces launch of secondary offering of common stock 11.02.2021 at 4:10 PM EST PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the Company, we or BridgeBio ) announced today the launch of a secondary public offe
Read more →BBIOBridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations
First-in-human Phase 1/2 trial in patients with venous malformations (VMs), lymphatic malformations (LMs), and venolymphatic malformations (VLMs) associated with PIK3CA or TEK mutations Clinical trial enrolling patients across multiple sites in the United States PALO ALTO, Cali
Read more →BBIOBridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. PALO ALTO, CA January 26, 2021 BridgeBio Pharma, Inc. ( BridgeBio ) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, I
Read more →BBIOBridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes
BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes PALO ALTO, Calif. January 25, 2021 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the Company, we or BridgeBio ) announced today that it intends to offer, subject to market conditions and other
Read more →BBIOBridgeBio Pharma, Inc. Prices Upsized Offering Of $650 Million Convertible Senior Notes
BridgeBio Pharma, Inc. Prices Upsized Offering Of $650 Million Convertible Senior Notes
Read more →BBIOStockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. PALO ALTO, Calif. and
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. PALO ALTO, Calif. and SAN FRANCISCO, January 19, 2021 BridgeBio Pharma, Inc. ( BridgeBio ) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. ( E
Read more →BBIOBridgeBio Pharma, Inc. And Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline For Eidos Stockholders
BridgeBio Pharma, Inc. And Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline For Eidos Stockholders
Read more →BBIOLeading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma And Eidos Therapeutics Stockholders Vote For The Proposed Merger
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma And Eidos Therapeutics Stockholders Vote For The Proposed Merger
Read more →BBIOUCSF And BridgeBio Pharma Collaborate To Accelerate The Development Of Therapies For Genetic Diseases
UCSF And BridgeBio Pharma Collaborate To Accelerate The Development Of Therapies For Genetic Diseases
Read more →BBIOBridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease
Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise Partnership Focused on Delivering Targeted Therapies for Genetically Defined Cardiovascular Diseases PALO ALTO, Calif. and SOUTH SAN FRANCISCO, Calif., Dec. 07, 2
Read more →BBIOBridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
• Application accepted under Priority Review designation • Application accepted into Real Time Oncology Review (RTOR) pilot program • This is BridgeBio’s second NDA acceptance • Application will also be submitted for review in Australia and Canada under Project Orbis PALO
Read more →BBIOBridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations
SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor (BBP-398) in patients with solid tumors driven by mutat
Read more →BBIOBridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update - Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio s clinical and commercial develop
BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update -Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio s clinical and commercial development infrastructure to bear upon Eidos Acoramidis - New Dr
Read more →BBIOBridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Phoenix Tissue Repair today announced that the first patient has been dosed in a Phase 2 study of BBP-589 (also known as PTR-01), an intravenously-administered recombinant collagen 7 (rC
Read more →BBIOBridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases
PALO ALTO, Calif. and DENVER, Oct. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus today announced a collaboration to advance novel research on genetically driven diseases into therapeutic applications for
Read more →BBIOBRIDGEBIO PHARMA AND EIDOS THERAPEUTICS ANNOUNCE MERGER AGREEMENT BridgeBio to Acquire All Outstanding Shares of Eidos it Does Not Already Own Agreement Brings BridgeBio s Clinical Development and Commercial Development
BRIDGEBIO PHARMA AND EIDOS THERAPEUTICS ANNOUNCE MERGER AGREEMENT BridgeBio to Acquire All Outstanding Shares of Eidos it Does Not Already Own Agreement Brings BridgeBio s Clinical Development and Commercial Development Infrastructure to Bear Upon Eidos Acoramidis, Creating An
Read more →BBIOForward-Looking Statements and Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amen
R&D Day September 29, 2020 Exhibit Forward-Looking Statements and Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
Read more →BBIOBridgeBio Pharma and Affiliate Origin Biosciences Announces FDA Acceptance of its New Drug Application for Fosdenopterin for the Treatment of MoCD Type A
Application accepted under Priority Review designation with Breakthrough Therapy Designation and Rare Pediatric Disease Designation previously granted There are currently no approved therapies for the treatment of MoCD Type A, which results in severe and irreversible neurologica
Read more →BBIOBridgeBio Pharma to Host Virtual R&D Day on September 29, 2020
PALO ALTO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, today announced that it will host its first R&D Day on Tuesday, September 29
Read more →BBIOBridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Topline proof-of-concept results in ADH1 anticipated in 2021 Currently, there are no approved therapies for ADH1 PALO ALTO, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of
Read more →BBIOBridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
$26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an equity interest in LianBio. BridgeBio CEO and founder Neil Kumar, Ph.D., has been appointe
Read more →BBIOBridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update -Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beg
BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update -Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020 -Strategic collaboration with Perceptive A
Read more →BBIOBridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results And Business Update
BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results And Business Update
Read more →BBIOBridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia
SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with the investigational medicine infigratinib, an orally available small molecule, that targe
Read more →BBIOBridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of MoCD Type A
BridgeBio Pharma's Origin Biosciences Announces FDA Approval Of NULIBRY (fosdenopterin) For The Treatment Of MoCD Type A
Read more →BBIOBridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting
BOSTON, July 10, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing Phase 1/2 study of PTR-01 (BBP-589), an intravenously-administered recombinant collagen 7
Read more →BBIOBridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors
BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors PALO ALTO, Calif., June 24, 2020 (GLOBE NEWSWIRE) BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused
Read more →BBIOBridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases
PALO ALTO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, has entered into a strategic collaboration with the University of Florida to translate research in genetically drive
Read more →BBIOBridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases
PALO ALTO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has entered into a collaboration agreement with Johns Hopkins University to support the tran
Read more →BBIOBridgeBio Pharma And Eidos Therapeutics Announce Definitive Merger Agreement
BridgeBio Pharma And Eidos Therapeutics Announce Definitive Merger Agreement
Read more →BBIOBridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
ML Bio Solutions has initiated a Phase 1 clinical trial of BBP-418 in healthy volunteers ML Bio Solutions’ sponsored lead-in study is enrolling patients with LGMD2i across twelve sites in the U.S. and internationally, in collaboration with the LGMD-GRASP consortium SAN FRANCISC
Read more →BBIOBridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, Q
Read more →BBIOBridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update -Ended quarter with $928 million in cash, cash equivalents and marketable securities
BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update -Ended quarter with $928 million in cash, cash equivalents and marketable securities SAN FRANCISCO, May 13, 2020 BridgeBio Pharma, Inc. (Nasdaq: BBIO), today reported its financial results f
Read more →BBIOBridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments
BOSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 study of PTR-01 (BridgeBio designation BBP-589), an intravenously-administered recombinant co
Read more →BBIOBridgeBio Pharma's QED Therapeutics Announces Preclinical Data Demonstrating Potential Of Low-dose Infigratinib In Achondroplasia
BridgeBio Pharma's QED Therapeutics Announces Preclinical Data Demonstrating Potential Of Low-dose Infigratinib In Achondroplasia
Read more →BBIOBridgeBio Pharma, Inc. To Present At Upcoming Investor Conference
BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference
Read more →BBIOBridgeBio Pharma's QED Therapeutics Announces Dosing Of First Patients In Phase 3 And Phase 2 Clinical Trials Of Infigratinib In Tumors With FGFR Genetic Alterations
BridgeBio Pharma's QED Therapeutics Announces Dosing Of First Patients In Phase 3 And Phase 2 Clinical Trials Of Infigratinib In Tumors With FGFR Genetic Alterations
Read more →BBIObridgebio pharma, inc. announces proposed offering of $350 million convertible senior notes 04.03.2020 at 7:00
bridgebio pharma, inc. announces proposed offering of $350 million convertible senior notes 04.03.2020 at 7:00 AM EST PALO ALTO, Calif., March 04, 2020 (GLOBE NEWSWIRE) BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the Company, we or BridgeBio ) announced today that it intends to off
Read more →BBIOBridgeBio Pharma, Inc. Prices Upsized Offering Of $475 Million Convertible Senior Notes
BridgeBio Pharma, Inc. Prices Upsized Offering Of $475 Million Convertible Senior Notes
Read more →BBIOBridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress Achieved multiple clinical and pre-clinical milestones across BridgeBio s pipeline Delivered pipeline expansi
BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress SAN FRANCISCO March 2, 2020 BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today is reporting its fourt
Read more →BBIOBridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board Of Directors
BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board Of Directors
Read more →BBIOBridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences
BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences
Read more →BBIOBridgeBio Pharma Grows Pipeline To 20+ Genetic Medicines With Four Assets Focused On Treating Genetically Driven Diseases At Their Source
BridgeBio Pharma Grows Pipeline To 20+ Genetic Medicines With Four Assets Focused On Treating Genetically Driven Diseases At Their Source
Read more →BBIOBridgeBio Pharma's Gene Therapy Subsidiaries Enter Strategic Partnership With Catalent For Dedicated Gene Therapy Development And Manufacturing Capacity
BridgeBio Pharma's Gene Therapy Subsidiaries Enter Strategic Partnership With Catalent For Dedicated Gene Therapy Development And Manufacturing Capacity
Read more →BBIOPellePharm Initiates Phase 2 Clinical Trial Of Patidegib Topical Gel For People With High Frequency Basal Cell Carcinoma
PellePharm Initiates Phase 2 Clinical Trial Of Patidegib Topical Gel For People With High Frequency Basal Cell Carcinoma
Read more →BBIOBridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma
BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma
Read more →BBIOBridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress - Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolio - Delivered pipeline growth with the
BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress - Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolio - Delivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy ty
Read more →BBIOBridgeBio Pharma's Origin Biosciences Enters Partnership With Medison To Commercialize BBP-870 In Israel For MoCD Type A
BridgeBio Pharma's Origin Biosciences Enters Partnership With Medison To Commercialize BBP-870 In Israel For MoCD Type A
Read more →BBIOBridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member Genentech veteran brings global commercial expertise to Board of Directors and will serve as a Special Advisor
BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member Genentech veteran brings global commercial expertise to Board of Directors and will serve as a Special Advisor PALO ALTO, Calif., December 16, 2019 BridgeBio Pharma, Inc. (NASDAQ: BBIO) today anno
Read more →BBIOBridgeBio Pharma, Inc. Appoints Eli Wallace As Chief Scientific Officer In Residence For Oncology Programs
BridgeBio Pharma, Inc. Appoints Eli Wallace As Chief Scientific Officer In Residence For Oncology Programs
Read more →BBIOBridgeBio Pharma's Origin Biosciences Initiates Rolling Submission Of New Drug Application With The U.S. FDA For BBP-870 For The Treatment Of MoCD Type A
BridgeBio Pharma's Origin Biosciences Initiates Rolling Submission Of New Drug Application With The U.S. FDA For BBP-870 For The Treatment Of MoCD Type A
Read more →BBIOPellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
Read more →BBIOBridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures AG10 was Well Tolerated with Median
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Rates of All-Cause Morta
Read more →BBIOBridgeBio Pharma Reports Third Quarter 2019 Financial Results And Highlights Portfolio Progress
BridgeBio Pharma Reports Third Quarter 2019 Financial Results And Highlights Portfolio Progress
Read more →BBIOBridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential In Two Rare Disease Indications At The European Society Of Gene And Cell Therapy Conference
BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential In Two Rare Disease Indications At The European Society Of Gene And Cell Therapy Conference
Read more →BBIOQED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia
QED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia
Read more →BBIOBridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics
BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics
Read more →BBIOIvy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
Read more →BBIOAlexion and BridgeBio Announce Japanese License Agreement for Eidos Transthyretin Amyloidosis (ATTR) Investigational Medicine - Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase
Alexion and BridgeBio Announce Japanese License Agreement for Eidos Transthyretin Amyloidosis (ATTR) Investigational Medicine - Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. &
Read more →BBIOAlexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine
Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine
Read more →BBIOBridgeBio Pharma's Origin Biosciences Presents New Data On The Natural History Of Molybdenum Cofactor Deficiency (MoCD) Type A At The SSIEM Conference
BridgeBio Pharma's Origin Biosciences Presents New Data On The Natural History Of Molybdenum Cofactor Deficiency (MoCD) Type A At The SSIEM Conference
Read more →BBIOBridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions
BridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions
Read more →BBIOBridgeBio Pharma Announces Pricing Of Its Initial Public Offering
BridgeBio Pharma Announces Pricing Of Its Initial Public Offering
Read more →BBIOBridgeBio Pharma Announces Filing Of Registration Statement For Proposed Initial Public Offering
BridgeBio Pharma Announces Filing Of Registration Statement For Proposed Initial Public Offering
Read more →BBIOEidos Therapeutics Initiates ATTRibute-CM, A Phase 3 Study Of AG10 In ATTR-CM With Registrational 12-month Endpoint
Eidos Therapeutics Initiates ATTRibute-CM, A Phase 3 Study Of AG10 In ATTR-CM With Registrational 12-month Endpoint
Read more →BBIOPhoenix Tissue Repair Doses First Patient In Phase 1/2 Clinical Trial Of PTR-01 (BBP-589) For Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phoenix Tissue Repair Doses First Patient In Phase 1/2 Clinical Trial Of PTR-01 (BBP-589) For Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Read more →BBIOBridgeBio Pharma Closes $299.2 Million Financing Round To Support Its Efforts To Target Genetic Disease At The Source
BridgeBio Pharma Closes $299.2 Million Financing Round To Support Its Efforts To Target Genetic Disease At The Source
Read more →BBIOEidos Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference
Eidos Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference
Read more →BBIOQED Therapeutics Announces A Collaboration With Foundation Medicine To Develop Companion Diagnostics For Infigratinib
QED Therapeutics Announces A Collaboration With Foundation Medicine To Develop Companion Diagnostics For Infigratinib
Read more →BBIOEidos Therapeutics Appoints William Lis To Board Of Directors
Eidos Therapeutics Appoints William Lis To Board Of Directors
Read more →BBIOPellePharm To Present At Piper Jaffray Healthcare Conference
PellePharm To Present At Piper Jaffray Healthcare Conference
Read more →BBIOLEO Pharma And PellePharm Announce $760 Million Collaboration To Advance Innovative Therapies For Rare Skin Diseases
LEO Pharma And PellePharm Announce $760 Million Collaboration To Advance Innovative Therapies For Rare Skin Diseases
Read more →BBIOEidos Therapeutics To Present At Two Upcoming Investor Conferences
Eidos Therapeutics To Present At Two Upcoming Investor Conferences
Read more →BBIOBridgeBio Pharma LLC Signs Joint Collaboration Agreement With Cincinnati Children's To Accelerate Development Of Genetic Disease Therapeutics
BridgeBio Pharma LLC Signs Joint Collaboration Agreement With Cincinnati Children's To Accelerate Development Of Genetic Disease Therapeutics
Read more →BBIOEidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy
Eidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy
Read more →BBIOEidos Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update
Eidos Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update
Read more →BBIOEidos Therapeutics To Host Conference Call And Webcast To Discuss Phase 2 Clinical Trial Results
Eidos Therapeutics To Host Conference Call And Webcast To Discuss Phase 2 Clinical Trial Results
Read more →BBIOEidos Therapeutics Receives Positive Opinion For Orphan Designation From The European Medicines Agency For AG10, A Potent Oral Stabilizer For The Treatment Of Transthyretin Amyloidosis
Eidos Therapeutics Receives Positive Opinion For Orphan Designation From The European Medicines Agency For AG10, A Potent Oral Stabilizer For The Treatment Of Transthyretin Amyloidosis
Read more →BBIOData Published In Nature Communications Demonstrates CoA Therapeutics' Potential To Treat Genetically Driven Pantothenate Kinase-associated Neurodegeneration (PKAN)
Data Published In Nature Communications Demonstrates CoA Therapeutics' Potential To Treat Genetically Driven Pantothenate Kinase-associated Neurodegeneration (PKAN)
Read more →BBIOQED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress
QED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress
Read more →BBIOPellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs
PellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs
Read more →BBIOEidos Therapeutics To Present Phase 2 Data For AG10 In TTR Amyloidosis Cardiomyopathy At The AHA 2018 Scientific Sessions In A Late-breaking Featured Science Oral Presentation
Eidos Therapeutics To Present Phase 2 Data For AG10 In TTR Amyloidosis Cardiomyopathy At The AHA 2018 Scientific Sessions In A Late-breaking Featured Science Oral Presentation
Read more →BBIOFDA Grants Orphan Drug Designation To Eidos Therapeutics' Product Candidate, AG10, For Treatment Of Transthyretin Amyloidosis
FDA Grants Orphan Drug Designation To Eidos Therapeutics' Product Candidate, AG10, For Treatment Of Transthyretin Amyloidosis
Read more →BBIOPellePharm To Present At Cantor Fitzgerald Global Healthcare Conference
PellePharm To Present At Cantor Fitzgerald Global Healthcare Conference
Read more →BBIOEidos Therapeutics To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology
Eidos Therapeutics To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology
Read more →BBIOEidos Therapeutics Presents Data From Its Phase 1 Clinical Trial Of AG10 At The 22nd Annual Scientific Meeting Of The Heart Failure Society Of America
Eidos Therapeutics Presents Data From Its Phase 1 Clinical Trial Of AG10 At The 22nd Annual Scientific Meeting Of The Heart Failure Society Of America
Read more →BBIOEidos Therapeutics Announces Publication Of AG10 Molecular Design In Journal Of Medicinal Chemistry
Eidos Therapeutics Announces Publication Of AG10 Molecular Design In Journal Of Medicinal Chemistry
Read more →BBIOQED Tx – A New Company Working On A Treatment For Achondroplasia
QED Tx – A New Company Working On A Treatment For Achondroplasia
Read more →BBIOEidos Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update
Eidos Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update
Read more →BBIOEidos Therapeutics Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters' Option To Purchase Additional Shares
Eidos Therapeutics Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters' Option To Purchase Additional Shares
Read more →BBIOEidos Therapeutics Announces Pricing Of Initial Public Offering
Eidos Therapeutics Announces Pricing Of Initial Public Offering
Read more →BBIONeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics
NeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics
Read more →BBIOPellePharm To Participate In The Cantor Fitzgerald Dermatology And Aesthetics Summit
PellePharm To Participate In The Cantor Fitzgerald Dermatology And Aesthetics Summit
Read more →BBIOBridgeBio Pharma Launches CoA Therapeutics To Target Coenzyme-A For Rare Genetic Disorders
BridgeBio Pharma Launches CoA Therapeutics To Target Coenzyme-A For Rare Genetic Disorders
Read more →BBIOBridgeBio Pharma Enters Into Agreement To Acquire Late Stage Therapy For Ultra-rare Disorder From Alexion; Launches Origin Biosciences To Develop And Commercialize Therapy
BridgeBio Pharma Enters Into Agreement To Acquire Late Stage Therapy For Ultra-rare Disorder From Alexion; Launches Origin Biosciences To Develop And Commercialize Therapy
Read more →BBIOPellePharm To Present At The 2018 UBS Global Healthcare Conference
PellePharm To Present At The 2018 UBS Global Healthcare Conference
Read more →BBIOPellePharm To Present Topical Patidegib And Skin Cancer Epidemiological Data At The 7th International Investigative Dermatology Meeting
PellePharm To Present Topical Patidegib And Skin Cancer Epidemiological Data At The 7th International Investigative Dermatology Meeting
Read more →BBIOEidos Therapeutics Initiates Phase 2 Clinical Trial For AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy
Eidos Therapeutics Initiates Phase 2 Clinical Trial For AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy
Read more →BBIOEidos Therapeutics Completes $64M Series B Financing
Eidos Therapeutics Completes $64M Series B Financing
Read more →BBIOEidos Therapeutics To Host Symposium On TTR Stabilization At The 16th International Symposium On Amyloidosis
Eidos Therapeutics To Host Symposium On TTR Stabilization At The 16th International Symposium On Amyloidosis
Read more →BBIOBridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing
BridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing
Read more →BBIOEidos Therapeutics To Present At 36th Annual J.P. Morgan Healthcare Conference
Eidos Therapeutics To Present At 36th Annual J.P. Morgan Healthcare Conference
Read more →BBIOPellePharm Appoints Sanuj K. Ravindran, M.D., As President And Chief Executive Officer
PellePharm Appoints Sanuj K. Ravindran, M.D., As President And Chief Executive Officer
Read more →BBIOBridgeBio Pharma Appoints Sanuj Ravindran, M.D., And Eric Michael David, M.D. As CEOs-in-Residence To Lead Dermatology And Gene Therapy Programs
BridgeBio Pharma Appoints Sanuj Ravindran, M.D., And Eric Michael David, M.D. As CEOs-in-Residence To Lead Dermatology And Gene Therapy Programs
Read more →BBIOFDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome
FDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome
Read more →BBIOPreclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis
Preclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis
Read more →BBIOEidos Therapeutics To Present Data On Its Potential Treatment For Transthyretin Amyloidosis At The American Heart Association
Eidos Therapeutics To Present Data On Its Potential Treatment For Transthyretin Amyloidosis At The American Heart Association
Read more →BBIOMD Anderson And BridgeBio Pharma Launch Navire Pharma To Develop Targeted Therapy For Patients With Difficult-to-treat Cancer
MD Anderson And BridgeBio Pharma Launch Navire Pharma To Develop Targeted Therapy For Patients With Difficult-to-treat Cancer
Read more →BBIOEidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer
Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer
Read more →BBIOBridgeBio Pharma Expands Investor Base, Raising An Additional $135 Million, And Discloses Genetic Disease Pipeline Programs
BridgeBio Pharma Expands Investor Base, Raising An Additional $135 Million, And Discloses Genetic Disease Pipeline Programs
Read more →BBIOPellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing
PellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing
Read more →BBIOBridgeBio Pharma Launches Eidos Therapeutics To Develop Targeted Therapy For Fatal Heart Disease
BridgeBio Pharma Launches Eidos Therapeutics To Develop Targeted Therapy For Fatal Heart Disease
Read more →BBIOBridgeBio Pharma Launches With A Focus On Precision Medicines For Genetic Diseases
BridgeBio Pharma Launches With A Focus On Precision Medicines For Genetic Diseases
Read more →BBIOPellePharm Launches With Financing From BridgeBio Pharma To Develop Topical Therapy For Basal Cell Carcinomas And Gorlin Syndrome
PellePharm Launches With Financing From BridgeBio Pharma To Develop Topical Therapy For Basal Cell Carcinomas And Gorlin Syndrome
Read more →Competitive Position
How BBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how BBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial